Therapie der Hyper phosphatämie bei renaler Osteopathie

T.H. Ittel

doi:10.1055/s-0037-1619860

Osteologie, Table of Contents

Osteologie 2008; 17(03): 142-147
DOI: 10.1055/s-0037-1619860

Renale Osteopathie

Schattauer GmbH

Therapie der Hyper phosphatämie bei renaler Osteopathie

Use of phosphate binding agents to control hyperphosphatemia in dialysis patients

T.H. Ittel

¹Hanse-Klinikum Stralsund, Medizinische Klinik (Chefarzt: Prof. Dr. Thomas H. Ittel)

› Author Affiliations

Abstract

Zusammenfassung

Die Therapie der Hyperphosphatämie basiert auf Phosphatbindern, adäquater Dialyse und diätetischen Maßnahmen. Neben aluminiumhaltigen Phosphatbindern, deren Einsatz mit einer erheblichen Toxizitätsproblematik belastet ist, stehen kalziumhaltige Phosphatbinder und die kalziumfreien Phosphatbinder Sevelamer und Lanthankarbonat zur Verfügung. Sevelamer scheint besonders geeignet für inzidente Dialysepatienten mit radiologisch nachweisbarem Gefäßkalk, da unter diesem Phosphatbinder weniger progrediente Gefäßverkalkungen beobachtet werden als unter Therapie mit kalziumhaltigen Phosphatbindern. Allerdings konnte bislang in kontrollierten Studien kein Nachweis erbracht werden, dass Sevelamer im Vergleich zu Kalziumacetat die kardiovaskuläre Mortalität bei prävalenten Dialysepatienten reduziert. Lanthankarbonat ist aufgrund seiner hohen Affinität zu Phosphat der effektivste aluminium- und kalziumfreie Phosphatbinder. Er ist besonders geeignet zur Reduktion einer unerwünscht positiven Kalziumbilanz unter als Phosphatbinder eingesetzten Kalziumsalzen und ist günstig für Patienten mit supprimiertem Parathormon. Daten zum Effekt auf die Progression von vaskulären Verkalkungen liegen mit Lanthankarbonat derzeit noch nicht vor.

Summary

Treatment of hyperphosphatemia with phosphate binders is an important therapeutic intervention in the management of mineral and bone disorders of chronic kidney disease. Available phosphate binding agents include aluminum compounds, that may have significant toxicity, calcium-based phosphate-binders and novel calcium-free drugs. Sevelamer hydrochloride, which lowers both phosphate and cholesterol has been shown to attenuate the progression of vascular calcification and may be especially useful in dialysis patients with prevalent calcifications. However,a large randomized study has failed to show that treatment with sevelamer versus calcium-based binders affects allcause or cardiovascular mortality in prevalent dialysis patients. Lanthanum carbonate is considereda very potent calcium-free phosphate binder with an affinity toward phosphate similar to that of aluminum, but lacking its toxicity. This review focuses on recent data that may guide the use of the diverse phosphate binding agents.

Schlüsselwörter

Phosphatbinder - Sevelamer - Lanthankarbonat - Hyperphosphatämie

Keywords

Calcium-based phosphate binders - sevelamer - lanthanum carbonate - hyperphosphatemia

Full Text

References

Literatur
1 Altmann P, Barnett ME, Finn WF. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int 2007; 71: 252-259.
2 Amin N. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant 2002; 17: 340-345.
3 Andress DL. Bone and mineral guidelines for patients with chronic kidney disease: a call for revision. Clin J Am Soc Nephrol 03: 179-183 2008;
4 Asmus HG, Braun J, Krause R. et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005; 20: 1653-1661.
5 Behets GJ, Dams G, Vercauteren SR. et al. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?J Am Soc Nephrol. 2004; 15: 2219-2228.
6 Behets GJ, Verberckmoes SC, D’Haese PC, De Broe ME. Lanthanum carbonate:a new phosphate binder. Curr Opin Nephrol Hypertens 2004; 13: 403-409.
7 Behets GJ, Verberckmoes SC, Oste L. et al. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 2005; 67: 1830-1836.
8 Block GA, Raggi P, Bellasi A. et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
9 Block GA, Spiegel DM, Ehrlich J. et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.
10 Capitanini A, Lupi A, Osteri F, Petrone I, Del Corso C, Straniti M, Gallieni M, Rossi A. Gastric pH, sevelamer hydrochloride and omeprazole. Clin Nephrol 2005; 64: 320-322.
11 Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
12 Coen G, Manni M, Mantella D. et al. Are PTH serum levels predictive of coronary calcifications in haemodialysis patients?. Nephrol Dial Transplant 2007; 22: 3262-3267.
13 D’Haese PC, Spasovski GB, Sikole A. et al. A multicenter study on the effects of lanthanum carbonate (FosrenolTM) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 63: S73-S78.
14 Eknoyan G, Levin A, Levin N. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (Suppl. 03) S1-S201.
15 Ferreira A, Frazao JM, Monier-Faugere MC. et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19: 405-412.
16 Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006; 65: 191-202.
17 Freemont AJ, Hoyland JA, Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 2005; 64: 428-437.
18 Garg JP, Chasan-Taber S, Blair A. et al. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum 2005; 52: 290-295.
19 Goodman WG, Goldin J, Kuizon BD. et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
20 Hutchison AJ, Maes B, Vanwalleghem J. et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 2006; 102: c61-c71.
21 Ittel TH. Determinants of gastrointestinal absorption and distribution of aluminium in health and uraemia. Nephrol Dial Transplant 1993; 08 (Suppl. 01) 17-24.
22 Ittel TH, Buddington B, Miller NL, Alfrey AC. Enhanced gastrointestinal absorption of aluminum in uremic rats. Kidney Int 1987; 32: 821-826.
23 Kalantar-Zadeh K, Kuwae N, Regidor DL. et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
24 Kestenbaum B, Sampson JN, Rudser KD. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
25 Ketteler M, Biggar P. After several years of witchhunting, can calcium-based phosphate binding be released on probation?. Nephrol Dial Transplant 2008; 23: 17-19.
26 Koiwa F, Onoda N, Kato H. et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005; 09: 340-346.
27 Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008; 73: 1296-1302.
28 Lindley E, Tattersall J, Wright M. Correction of metabolic acidosis after conversion from sevelamer hydrochloride to lanthanum carbonate. NDT Plus 2008; 01: 196.
29 Manns B, Klarenbach S, Lee H. et al. Economicevaluationofsevelamerinpatientswithend-stagerenaldisease. Nephrol Dial Transplant 2007; 22: 2867-2878.
30 McIntyre CW, Patel V, Taylor GS, Fluck RJA. prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant 2002; 17: 1643-1648.
31 Oka Y, Miyazaki M, Takatsu S. et al. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. Ther Apher Dial 2007; 11: 107-113.
32 Phan O, Ivanovski O, Nikolov IG. et al. Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE-/-) mice with chronic renal failure. Nephrol Dial Transplant 2008; 23: 82-90.
33 Qunibi W, Moustafa M, Muenz LR. et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008; 51: 952-965.
34 Qunibi WY, Hootkins RE, McDowell LL. et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004; 65: 1914-1926.
35 Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 2004; 13: 134-141.
36 Raggi P, James G, Burke SK. et al. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005; 20: 764-772.
37 Russo D, Miranda I, Ruocco C. et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255-1261.
38 Salusky IB. A new era in phosphate binder therapy: What are the options?. Kidney Int 2006; Suppl: S10-S15.
39 Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007; 02: 1241-1248.
40 Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005; 68: 2809-2813.
41 St Peter WL, Liu J, Weinhandl E, Fan QA. comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 2008; 51: 445-454.
42 Steinhausen C, Kislinger G, Winklhofer C. et al. Investigation of the aluminium biokinetics in humans: a 26Al tracer study. Food Chem Toxicol 42: 363-371 2004;
43 Suki WN, Zabaneh R, Cangiano JL. et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72: 1130-1137.
44 Tentori F, Hunt WC, Stidley CA. et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865.
45 Tomiyama C, Higa A, Dalboni MA. et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant 2006; 21: 2464-2471.
46 Tonelli M, Sacks F, Pfeffer M. et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112: 2627-2633.
47 Tonelli M, Wiebe N, Culleton B. et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22: 2856-2866.
48 Voormolen N, Noordzij M, Grootendorst DC. et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007; 22: 2909-2916.
49 Young EW, Albert JM, Satayathum S. et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187.